NCT00479128 2026-04-16
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
73 trialsNCT04940286 2026-04-16
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05497778 2026-04-16
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04481204 2026-04-15
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05616624 2026-04-15
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03609216 2026-04-13
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05632328 2026-04-08
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT03093922 2026-04-07
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02135042 2026-04-03
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NCT05984602 2026-03-30
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
Phase 1 Active not recruiting
NCT04960618 2026-03-23
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02422381 2026-02-18
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Providence Health & Services
Phase 1/2 Active not recruiting
NCT05451290 2026-02-12
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT05908747 2026-02-10
Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT06015659 2026-02-09
ZN-c3 + Gemcitabine in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02336087 2026-02-04
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03598595 2026-02-04
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06027268 2026-02-03
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05500092 2026-01-28
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Montefiore Medical Center
Phase 2 Active not recruiting
NCT04630730 2026-01-21
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT05026905 2026-01-20
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT05524168 2026-01-15
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06076837 2026-01-12
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
Phase 1 Active not recruiting
NCT03587662 2026-01-09
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02989584 2026-01-07
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04241276 2026-01-07
STARPAC2
Queen Mary University of London
Phase 2 Active not recruiting
NCT06115499 2026-01-07
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2/3 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT02151084 2025-12-16
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT02481635 2025-12-08
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 1/2 Active not recruiting
NCT05975307 2025-12-01
BCIRT-01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT02921022 2025-11-26
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT03137771 2025-11-25
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Active not recruiting
NCT07243288 2025-11-21
RADIOPAN
Assistance Publique - Hôpitaux de Paris
Active not recruiting
NCT04386746 2025-11-17
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT01878617 2025-11-13
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02420847 2025-11-10
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02495896 2025-11-10
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT04821284 2025-11-04
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Thomas Jefferson University
Phase 1/2 Active not recruiting
NCT01972919 2025-10-27
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT02621151 2025-10-07
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NYU Langone Health
Phase 2 Active not recruiting
NCT00082706 2025-09-09
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04669197 2025-08-15
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting
NCT06018883 2025-08-07
PTCA199-3
Fudan University
Phase 3 Active not recruiting
NCT04907370 2025-07-16
DIAMOND
Sun Yat-sen University
Phase 3 Active not recruiting
NCT02755272 2025-07-04
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting